参考文献/References:
[1] Stringer T, Femia AN. Raynaud’s phenomenon: Current concepts[J]. Clin Dermatol, 2018, 36(4): 498-507.
[2] Neumeister MW. The role of botulinum toxin in vasospastic disorders of the hand[J]. Hand Clin, 2015, 31(1): 23-37.
[3] Fardoun MM, Nassif J, Issa K, et al. Raynaud’s phenomenon: a brief review of the underlying mechanisms[J]. Front Pharmacol, 2016, 7: 438.
[4] Munir S, Freidin MB, Brain S, et al. Association of raynaud’s phenomenon with a polymorphism in the NOS1 gene[J]. PLoS One, 2018, 13(4): e0196279.
[5] Vihlborg P, Graff P, Hagenbj?k A, et al. Serum metabolites in Hand-Arm vibration exposed workers[J]. Journal of Occupational and Environmental Medicine, 2020, 62(7): 460-465.
[6] Motegi S, Uehara A, Yamada K, et al. Efficacy of botulinum toxin B injection for raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis[J]. Acta Derm Venereol, 2017, 97(7): 843-850.
[7] Habib SM, Brenninkmeijer E, Vermeer MH, et al. Botulinum toxin type A in the treatment of Raynaud’s phenomenon[J]. Dermatol Ther, 2020,33(6): e14182.
[8] Dhaliwal K, Griffin MF, Salinas S, et al. Optimisation of botulinum toxin type a treatment for the management of Raynaud’s phenomenon using a dorsal approach: a prospective case series[J]. Clin Rheumatol, 2019, 38(12): 3669-3676.
[9] Asad U, Austin B, Tarbox M, et al. Botulinum toxin in the Long-Term treatment of refractory raynaud’s phenomenon[J]. J Drugs Dermatol, 2019, 18(9): 943-945.
[10] 张小龙汤建平靳令经.A型肉毒毒素治疗雷诺现象一例[J].中华神经科杂志,2013,46(9):646-647.
[11] Zhang X, Hu Y, Nie Z, et al. Treatment of raynaud’s phenomenon with botulinum toxin type a[J]. Neurol Sci, 2015, 36(7): 1225-1231.
[12] Motegi S, Sekiguchi A, Saito S, et al. Successful treatment of Raynaud’s phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary[J]. J Dermatol, 2018, 45(3): 349-352.
[13] Zebryk P, Puszczewicz MJ. Botulinum toxin A in the treatment of Raynaud’s phenomenon:a systematic review[J]. Arch Med Sci, 2016, 12(4): 864-870.
[14] Grando S, Zachary CB. The non-neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond[J]. Br J Dermatol, 2018, 178(5): 1011-1019.
[15] Deltombe T, Lejeune T, Gustin T. Botulinum toxin type A or selective neurotomy for treating focal spastic muscle overactivity?[J]. Ann Phys Rehabil Med, 2019, 62(4): 220-224.
[16] 肉毒毒素治疗应用专家组.中华医学会神经病学分会帕金森病及运动障碍学组.中国肉毒毒素治疗应用专家共识[J].中华神经科杂志,2018,51(10):779-786.
[17] Neumeister MW, Webb KN, Romanelli M. Minimally invasive treatment of Raynaud phenomenon: the role of botulinum type A[J]. Hand Clin, 2014, 30(1): 17-24.
[18] Segreto F, Marangi GF, Cerbone V, et al. The role of botulinum toxin a in the treatment of raynaud phenomenon[J]. Ann Plast Surg, 2016, 77(3): 318-323.
[19] Wissel J, Bensmail D, Ferreira JJ, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The Tower study[J]. Neurology, 2017, 88(14): 1321-1328.
[20] Zhou Y, Liu Y, Hao Y, et al. The mechanism of botulinum A on Raynaud syndrome[J]. Drug Des Devel Ther, 2018, 12: 1905-1915.
[21] Wu X, Zhang Y, Chen L, et al. BTX-A promotes expression of Angiogenesis-Associated genes in human umbilical vein endothelial cells[J]. DNA Cell Biol, 2020, 39(12): 2154-2165.
[22] 汪海洋,张一凡,孙建明.雷诺综合征的诊治进展[J].重庆医学,2017,46(19):2721-2724.
[23] Hughes M, Allanore Y, Chung L, et al. Raynaud phenomenon and digital ulcers in systemic sclerosis[J]. Nat Rev Rheumatol, 2020, 16(4): 208-221.
[24] Lobb DC, Pierce J, Perry M, et al. The use of ultrasound guidance for the treatment of raynaud disease of the hand with botulinum toxin[J]. Ann Plast Surg, 2020, 84(6S Suppl 5): S386-S388.
[25] 王芳,李曼,杜鹃等.甲皱襞毛细血管镜在自身免疫性皮肤病中的应用[J].中国皮肤性病学杂志,2020:1-15.
[26] Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating Scleroderma-Associated raynaud’s phenomenon: a randomized, Double-Blind, Placebo-Controlled clinical trial[J]. Arthritis Rheumatol, 2017, 69(8): 1661-1669.
[27] Sycha T, Graninger M, Auff E, et al. Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study[J]. Eur J Clin Invest, 2004, 34(4): 312-313.
[28] Wang L, Lei QS, Liu YY, et al. A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer[J]. Medicine(Baltimore), 2016, 95(40): e5092.
[29] Nagarajan M, Mcarthur P. Targeted high concentration botulinum toxin A injections in patients with Raynaud’s phenomenon: a retrospective single-centre experience[J]. Rheumatol Int, 2020: 1-7.
[30] Quintana Castanedo Lucía FRMM. Ischemic ulcers of the toes secondary to Raynaud’s phenomenon in a child successfully treated with botulinum toxin[J]. Pediatr Dermatol, 2020, 37(4):1-3.